LQDA

LIQUIDIA CORP

Healthcare | Mid Cap

$0.80

EPS Forecast

$190.9

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Liquidia’s Q3 2026: YUTREPIA Gains Traction as Litigation Settlement Clears the Air

Overview: A quarter of growth tempered by one-off charges

Liquidia Corporation, NASDAQ: LQDA, reported third-quarter results for the period ended September 30, 2026. The headline numbers tilt positive on core demand: YUTREPIA® (treprostinil) inhalation powder delivered net product sales of $222.7 million in Q3 2026, a 31% sequential lift from the prior quarter. For investors tracking EPS and EPS consensus, the quarter was defined by a GAAP net loss of $236.3 million, rooted in a $389.7 million litigation settlement charge. In other words, the company’s operating momentum exists alongside a one-time accounting drag that masks the underlying trajectory of the business. No formal revenue forecast for YUTREPIA beyond Q3 was issued in the release, but the growth signal is clear enough to keep eyes on a rising earnings trajectory through non‑GAAP metrics.

Quarter Highlights

  • Net product sales of $222.7 million in the third quarter of 2026, up 31% from Q2 2026.
  • October 2026 total patient shipments reached their highest monthly level since launch.
  • Resolved all litigation with United Therapeutics via a global settlement, securing continuity of care for all patients treated with YUTREPIA.
  • Reported net loss of $236.3 million, reflecting a $389.7 million settlement charge related to litigation.
  • Five consecutive quarters of rising non-GAAP, adjusted EBITDA, now at $140.5 million.
  • Cash and cash equivalents rose to $396.1 million prior to settlement payments.
  • Granted Fast Track designation to YUTREPIA for the treatment of systemic sclerosis–associated Raynaud’s phenomenon (SSc-RP) and initiated RE-WARM, a Phase 2 open-label dose-finding study.

Leadership view

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, framed the results as a reset with momentum. “Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy,” he said. With litigation resolved and commercial availability secure, the company aims to cement YUTREPIA’s value through Phase 4 studies in PAH and to advance its inhaled treprostinil pipeline from L606 in PAH and PH-ILD to indications where patients have no approved options, such as SSc-RP and PH-COPD.”

YUTREPIA Commercial Highlights

  • Net product sales of $222.7 million in Q3 2026.
  • Paid patient demand was $212.2 million in Q3 2026, excluding voucher and patient access programs, underscoring growing patient demand.
  • From launch through September 2026, more than 60% of referrals included a PAH diagnosis, rising to more than 70% in September.
  • In October 2026, total patient shipments reached their highest monthly level since launch.
  • October 2026 also saw a continuation of improved daily referral rate, contributing to a favorable demand backdrop.

Financials in Context

The quarter’s GAAP loss was heavily influenced by a substantial one-time charge ($389.7 million) tied to the litigation settlement with United Therapeutics. Excluding this charge, the company points to a five-quarter streak of rising non-GAAP, adjusted EBITDA, suggesting improving operating efficiency and a path toward cash flow generation. While the EPS figure on a GAAP basis is negative due to the settlement, management emphasizes the strength of the core YUTREPIA business and its ability to fund ongoing development programs. The liquidity position—~$396 million in cash and equivalents before settlement payments—provides a runway to advance the pipeline while continuing to scale commercial adoption.

Pipeline and Strategic Outlook

Beyond the current quarters, Liquidia is pushing forward with a portfolio that could alter the competitive landscape for inhaled prostacyclin therapies. The company has granted Fast Track designation to YUTREPIA for SSc-RP and kicked off RE-WARM, a Phase 2 dose-finding study. Strategically, Liquidia is positioning L606 for PAH and PH-ILD, while exploring new indications where patients lack approved options, such as SSc-RP and PH-COPD. The combination of ongoing clinical work and a cleared litigation path sets the stage for potential earnings catalysts if Phase 4 data in PAH proves durable and if payer dynamics align with continued market access.

Implications for Liquidia and Sector Peers

The settlement removes a credible overhang from Liquidia’s story, reducing near-term regulatory and litigation risk that often weighs on smaller biopharma names. For peers developing inhaled therapies, the takeaway is twofold: a credible commercial uptake story in PAH can coexist with meaningful one-time charges, and a constructive regulatory path (as evidenced by Fast Track designations) can accompany a robust operating trajectory even in a competitive space.

In terms of the revenue forecast for the core YUTREPIA franchise, investors will likely scrutinize the rate of payer acceptance, referral quality, and the durability of patient demand as the company expands into additional PAH demographics and new indications. The EPS consensus for the coming quarters will be a function not just of YUTREPIA sales, but of how aggressively Liquidia can optimize its expense structure once the one-time charges roll off the books. If the non-GAAP EBITDA trend persists, the market could assign a higher multiple to the underlying business despite current GAAP losses.

Conclusion: A quarter that reminds you why science and finance share stage time

Liquidia’s Q3 2026 results illustrate a biotech company balancing a meaningful commercial ramp with the reality of a legal settlement that altered the bottom line. YUTREPIA is establishing a credible footprint in PAH, with expanding patient demand and a rising monthly shipment cadence. As the company continues to push L606 and pursue additional indications, the next few quarters will reveal whether the non-GAAP narrative can outpace the GAAP accounting drumbeat. For investors, the key metrics to watch remain EPS metrics in the context of settlements, the trajectory of YUTREPIA’s revenue base, and the pace of progress in the pipeline that could redefine Liquidia’s competitive horizon.